COO Stock Analysis: Buy, Sell, or Hold?
COO - The Cooper Companies, Inc. Common Stock
$59.61
-0.77 (-1.28%)
▼
5d:
-0.65%
30d:
-14.08%
90d:
-28.17%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: Jun 04, 2026
18d
Smart Money Accumulation
COO is down 3.2% this week, but smart money is accumulating calls. Top strike: $65 2026-06-18 with 197 OI. Call ratio: 94% View Scanner →
Strength: 6.0/10
Get Alerted When COO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: COO appears deeply undervalued. Market expects -8.6% annual earnings decline despite 27% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: COO appears deeply undervalued. Market expects -8.6% annual earnings decline despite 27% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$106.49
Based on 6.4% avg growth
INTRINSIC VALUE TODAY
$66.12
9.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: COO is currently trading at $59.61, which is considered oversold relative to its 30-day fair value range of $60.73 to $69.80. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.9) compared to its historical average (15.6). Remarkably, the market is currently pricing in an annual earnings decline of 8.6% over the next few years. This pessimistic expectation contrasts with the company's recent 26.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, COO is in a strong downtrend. The price is currently testing key support at $58.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $91.07 (+52.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, COO is in a strong downtrend. The price is currently testing key support at $58.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $91.07 (+52.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$60.73 -
$69.80
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 52.8% below Wall St target ($91.07)
Trading Range Analysis
30-Day Trading Range
$60.73 -
$69.80
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$58.89
Resistance Level
$62.87
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.87
Wall Street Target
$91.07
(+52.8%)
Revenue Growth (YoY)
6.2%
Earnings Growth (YoY)
26.9%
Profit Margin
9.7%
Valuation Discount vs History
-8.6% cheaper
PE vs Historical
11.9 vs 15.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.6%
(market-implied from PE analysis)
1-Year Target
$54.48
(-9%)
2-Year Target
$49.80
(-17%)
3-Year Target
$45.52
(-24%)
3-Yr Target (if PE normalizes)
(PE: 12→16)
$59.80
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 8.7%)
$142.48
(+139%)
Base:
(SPY PE: 11.9, Growth: 8.7%)
$76.65
(+29%)
Bear:
(PE: 10.1, Growth: 8.7%)
$65.15
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 30.04 | Current EPS (TTM): $2.01
Bull Case
$132.84
(+123%)
Analyst growth 100.0%, PE expands to 33.0
Base Case
$120.76
(+103%)
Market implied 100.0%, PE stable at 30.0
Bear Case
$41.06
(-31%)
Severe decline -20.0%, PE contracts to 25.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.9 to 15.6
Stabilization Target:
$78.32
(+31.4%)
PE Expansion Potential:
+31.4%
Share & Embed Analysis
Last updated: May 16, 2026 8:31 AM ET
Data refreshes hourly during market hours. Next update: 9:31 AM
Data refreshes hourly during market hours. Next update: 9:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is COO showing a specific setup today?
Insider Activity (6 Months)
6
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Cynthia L Lucchese
BUY
1784 shares
2025-12-22
Maria Rivas
BUY
1000 shares
2025-12-18
Lawrence Erik Kurzius
BUY
2000 shares
2025-12-17
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$577 | 58 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$88 | 53 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$271 | 59 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$180 | 49 HOLD |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$350 | 58 HOLD |
Advanced COO Option Strategies
Professional options setups generated by AI based on today's COO price and gamma walls.
